12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DiaPep277: Completed Phase III enrollment

Clal's Andromeda Biotech Ltd. subsidiary completed enrollment of 475 newly diagnosed Type I diabetics with residual beta cell function ages 20-45 in the double-blind, placebo-controlled, international Phase III trial (DIA-AID 2). The trial is evaulating 1 mg subcutaneous DiaPep277 administered every 3 months for 2 years. The...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >